Diagnostics sales up in local currencies at Roche:
This article was originally published in Clinica
Diagnostics sales at Roche fell 10% to SwFr 490 million ($434 million) in the first quarter of 1995, compared with the same period last year. However, this masked a 4% rise in diagnostic sales in local currencies. At the end of April, shareholders approved Roche Biomedical Lab's merger with National Health Labs (see Clinica No 653, p 15). Group sales increased 2% in SwFr terms (15% in local currencies) to SwFr 5,075 million in the first quarter compared with the same period last year. This was due mainly to strong growth in pharmaceutical sales.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.